Consistently Good Clinical Response in Patients with Early Axial Spondyloarthritis After 3 Years of Continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial

REFERENCES

1. 1.↵
   1. Rudwaleit M,
   2. van der Heijde D,
   3. Landewe R,
   4. Listing J,
   5. Akkoc N,
   6. Brandt J,
   7. et al.

   The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Song IH,
   2. Hermann K,
   3. Haibel H,
   4. Althoff C,
   5. Listing J,
   6. Burmester G,
   7. et al.

   Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011;70:590–6.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Barkham N,
   2. Keen HI,
   3. Coates LC,
   4. O’Connor P,
   5. Hensor E,
   6. Fraser AD,
   7. et al.

   Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009;60:946–54.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Sieper J,
   2. van der Heijde D,
   3. Dougados M,
   4. Mease PJ,
   5. Maksymowych WP,
   6. Brown MA,
   7. et al.

   Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815–22.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Landewé R,
   2. Braun J,
   3. Deodhar A,
   4. Dougados M,
   5. Maksymowych WP,
   6. Mease PJ,
   7. et al.

   Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39–47.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Haibel H,
   2. Heldmann F,
   3. Listing J,
   4. Kupper H,
   5. Braun J,
   6. Sieper J

   . Long-term efficacy of adalimumab after drug withdrawal and retreatment of flare patients in active non-radiographic, axial spondyloarthritis. Arthritis Rheum 2013;65:2211–3.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Davis JC Jr.,
   2. van der Heijde DM,
   3. Braun J,
   4. Dougados M,
   5. Clegg DO,
   6. Kivitz AJ,
   7. et al.

   Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346–52.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Sieper J,
   2. van der Heijde D,
   3. Dougados M,
   4. Brown LS,
   5. Lavie F,
   6. Pangan AL

   . Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:700–6.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. van der Linden S,
   2. Valkenburg HA,
   3. Cats A

   . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Song IH,
    2. Althoff CE,
    3. Haibel H,
    4. Hermann KG,
    5. Poddubnyy D,
    6. Listing J,
    7. et al.

    Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012;71:1212–5.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Robinson PC,
    2. Wordsworth BP,
    3. Reveille JD,
    4. Brown MA

    . Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis 2013;72:162–4.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Sieper J,
    2. van der Heijde D

    . Non-radiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum 2013;65:543–51.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Song IH,
    2. Weiss A,
    3. Hermann KG,
    4. Haibel H,
    5. Althoff CE,
    6. Poddubnyy D,
    7. et al.

    Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 2013;72:823–5.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Braun J,
    2. Baraliakos X,
    3. Brandt J,
    4. Listing J,
    5. Zink A,
    6. Alten R,
    7. et al.

    Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 2005;44:670–6.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Baraliakos X,
    2. Brandt J,
    3. Listing J,
    4. Haibel H,
    5. Sorensen H,
    6. Rudwaleit M,
    7. et al.

    Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856–63.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Lambert RG,
    2. Salonen D,
    3. Rahman P,
    4. Inman RD,
    5. Wong RL,
    6. Einstein SG,
    7. et al.

    Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007;56:4005–14.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Smolen JS,
    2. Braun J,
    3. Dougados M,
    4. Emery P,
    5. Fitzgerald O,
    6. Helliwell P,
    7. et al.

    Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Poddubnyy D,
    2. Haibel H,
    3. Listing J,
    4. Marker-Hermann E,
    5. Zeidler H,
    6. Braun J,
    7. et al.

    Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64:1388–98.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Ramiro S,
    2. van Tubergen AM,
    3. van der Heijde D,
    4. Stolwijk C,
    5. Dougados M,
    6. Van den Bosch F,
    7. et al.

    Higher disease activity leads to more damage in the early phases of ankylosing spondylitis: 12-year data from the OASIS cohort. Arthritis Rheum 2013;65 Suppl 10:S1215.

    OpenUrl
20. 20.↵
    1. Bennett AN,
    2. McGonagle D,
    3. O’Connor P,
    4. Hensor EM,
    5. Sivera F,
    6. Coates LC,
    7. et al.

    Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008;58:3413–8.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Oostveen J,
    2. Prevo R,
    3. den Boer J,
    4. van de Laar M

    . Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol 1999;26:1953–8.

    OpenUrlPubMed
22. 22.↵
    1. Maksymowych WP,
    2. Chiowchanwisawakit P,
    3. Clare T,
    4. Pedersen SJ,
    5. Ostergaard M,
    6. Lambert RG

    . Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93–102.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Maksymowych WP,
    2. Morency N,
    3. Conner-Spady B,
    4. Lambert RG

    . Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013;72:23–8.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Baraliakos X,
    2. Listing J,
    3. Rudwaleit M,
    4. Sieper J,
    5. Braun J

    . The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008;10:R104.

    OpenUrlCrossRefPubMed